Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Papillary Renal Cell Carcinoma

Papillary Renal Cell Carcinoma

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Papillary Renal Cell Carcinoma

3 trials tracked for Papillary Renal Cell Carcinoma.

3Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 3
  1. Phase 2 Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Completed
  2. Phase 2 Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer Completed
  3. Phase 2 Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Savolitinib and durvalumab combination yields response rates of 34% to 53% in papillary renal cancer patients
Oncology Phase II
Savolitinib and durvalumab combination yields response rates of 34% to 53% in papillary renal cancer patients New Hope for a Tough Kidney Cancer Type
This single-arm phase II study evaluated savolitinib and durvalumab in 41 treatment-naïve or pretreated patients with papillary renal cancer…
A new drug pair breaks the shield blocking treatment for a rare kidney cancer type, offering patients a chance at longer survival after stan…
Apr 20, 2026